Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroidectomy | 13 | 2023 | 915 | 2.880 |
Why?
|
Thyroid Neoplasms | 22 | 2024 | 2360 | 2.540 |
Why?
|
Physicians, Women | 5 | 2021 | 519 | 1.530 |
Why?
|
Hypocalcemia | 2 | 2023 | 203 | 1.490 |
Why?
|
Thyroid Nodule | 11 | 2024 | 766 | 1.450 |
Why?
|
Awards and Prizes | 3 | 2021 | 365 | 1.210 |
Why?
|
Fibromatosis, Aggressive | 3 | 2015 | 125 | 1.120 |
Why?
|
Adenocarcinoma, Follicular | 4 | 2022 | 325 | 1.080 |
Why?
|
General Surgery | 8 | 2023 | 1714 | 0.870 |
Why?
|
beta Catenin | 3 | 2014 | 1048 | 0.800 |
Why?
|
Parathyroid Hormone | 4 | 2023 | 1804 | 0.760 |
Why?
|
Parathyroidectomy | 2 | 2013 | 244 | 0.690 |
Why?
|
Intestinal Neoplasms | 3 | 2014 | 317 | 0.680 |
Why?
|
Carcinoma, Papillary | 6 | 2022 | 792 | 0.660 |
Why?
|
Carcinoma | 5 | 2018 | 2341 | 0.660 |
Why?
|
Internship and Residency | 7 | 2023 | 5952 | 0.620 |
Why?
|
Job Satisfaction | 2 | 2019 | 549 | 0.570 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2016 | 59 | 0.530 |
Why?
|
Endocrinology | 1 | 2021 | 443 | 0.500 |
Why?
|
Hymecromone | 1 | 2015 | 9 | 0.490 |
Why?
|
Cytodiagnosis | 3 | 2018 | 452 | 0.480 |
Why?
|
Adenocarcinoma, Papillary | 2 | 2012 | 85 | 0.480 |
Why?
|
Faculty, Medical | 2 | 2020 | 1218 | 0.470 |
Why?
|
Adenoma | 5 | 2018 | 2163 | 0.470 |
Why?
|
Parathyroid Neoplasms | 2 | 2018 | 244 | 0.460 |
Why?
|
Neoplasm Invasiveness | 5 | 2021 | 3637 | 0.460 |
Why?
|
Vitamin D Deficiency | 1 | 2023 | 1389 | 0.440 |
Why?
|
Leadership | 2 | 2021 | 1395 | 0.420 |
Why?
|
Lymph Node Excision | 1 | 2019 | 1276 | 0.420 |
Why?
|
Hypoparathyroidism | 1 | 2014 | 136 | 0.410 |
Why?
|
Mesenchymal Stem Cells | 2 | 2015 | 1671 | 0.410 |
Why?
|
src-Family Kinases | 2 | 2012 | 539 | 0.400 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2018 | 595 | 0.390 |
Why?
|
Hyaluronic Acid | 1 | 2015 | 489 | 0.370 |
Why?
|
Terminology as Topic | 1 | 2018 | 1539 | 0.370 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2013 | 164 | 0.360 |
Why?
|
Burnout, Professional | 1 | 2019 | 712 | 0.360 |
Why?
|
Estrogen Receptor beta | 2 | 2013 | 172 | 0.360 |
Why?
|
Oligonucleotides | 1 | 2014 | 564 | 0.360 |
Why?
|
Sulindac | 1 | 2010 | 29 | 0.360 |
Why?
|
Biopsy, Fine-Needle | 8 | 2024 | 1131 | 0.350 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2011 | 125 | 0.350 |
Why?
|
Cell Proliferation | 5 | 2018 | 10494 | 0.340 |
Why?
|
Thyroid Gland | 5 | 2019 | 1172 | 0.340 |
Why?
|
Cell Nucleus | 1 | 2018 | 2889 | 0.330 |
Why?
|
Intraoperative Care | 1 | 2013 | 772 | 0.330 |
Why?
|
Authorship | 2 | 2022 | 287 | 0.310 |
Why?
|
Lymph Nodes | 2 | 2021 | 3472 | 0.310 |
Why?
|
Societies, Medical | 4 | 2021 | 3955 | 0.290 |
Why?
|
Tyrosine | 1 | 2012 | 1428 | 0.290 |
Why?
|
Estrogen Receptor alpha | 2 | 2013 | 582 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2010 | 727 | 0.270 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2024 | 9425 | 0.270 |
Why?
|
Genes, APC | 1 | 2007 | 145 | 0.270 |
Why?
|
Congresses as Topic | 2 | 2021 | 810 | 0.260 |
Why?
|
Postoperative Complications | 7 | 2023 | 15880 | 0.260 |
Why?
|
Retrospective Studies | 22 | 2024 | 81834 | 0.260 |
Why?
|
Proto-Oncogene Proteins B-raf | 5 | 2023 | 2072 | 0.250 |
Why?
|
Specialties, Surgical | 2 | 2020 | 393 | 0.250 |
Why?
|
Calcium | 4 | 2023 | 5793 | 0.250 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2018 | 736 | 0.240 |
Why?
|
Humans | 64 | 2024 | 768451 | 0.240 |
Why?
|
Female | 45 | 2024 | 396943 | 0.230 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13708 | 0.230 |
Why?
|
Wound Healing | 2 | 2015 | 2819 | 0.230 |
Why?
|
Male | 40 | 2024 | 364781 | 0.230 |
Why?
|
Adrenalectomy | 2 | 2018 | 348 | 0.220 |
Why?
|
Endocrine Surgical Procedures | 1 | 2023 | 32 | 0.220 |
Why?
|
Melanoma | 2 | 2019 | 5740 | 0.210 |
Why?
|
Middle Aged | 31 | 2024 | 223418 | 0.210 |
Why?
|
Paget Disease, Extramammary | 1 | 2022 | 52 | 0.190 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2010 | 2434 | 0.190 |
Why?
|
Precancerous Conditions | 1 | 2008 | 988 | 0.180 |
Why?
|
Sulfonamides | 2 | 2008 | 1988 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2021 | 2465 | 0.180 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2021 | 2067 | 0.180 |
Why?
|
Surgical Wound Dehiscence | 1 | 2022 | 216 | 0.180 |
Why?
|
Pyrazoles | 2 | 2008 | 2024 | 0.180 |
Why?
|
Mutation | 7 | 2023 | 30243 | 0.170 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2021 | 2884 | 0.170 |
Why?
|
Adult | 28 | 2024 | 223542 | 0.170 |
Why?
|
Watchful Waiting | 1 | 2024 | 496 | 0.170 |
Why?
|
Adenocarcinoma, Sebaceous | 1 | 2019 | 21 | 0.170 |
Why?
|
Sebaceous Gland Neoplasms | 1 | 2019 | 40 | 0.170 |
Why?
|
Reoperation | 4 | 2021 | 4342 | 0.170 |
Why?
|
Aged, 80 and over | 13 | 2021 | 59680 | 0.160 |
Why?
|
Neoplasm Staging | 5 | 2021 | 11249 | 0.160 |
Why?
|
Ultrasonography | 9 | 2024 | 5995 | 0.150 |
Why?
|
Hydroxyprostaglandin Dehydrogenases | 1 | 2018 | 31 | 0.150 |
Why?
|
Minority Groups | 2 | 2023 | 1215 | 0.150 |
Why?
|
Faculty | 1 | 2021 | 384 | 0.150 |
Why?
|
Students, Medical | 2 | 2023 | 1962 | 0.150 |
Why?
|
Intestinal Mucosa | 2 | 2013 | 3048 | 0.150 |
Why?
|
Aged | 23 | 2024 | 171520 | 0.150 |
Why?
|
Tumor Cells, Cultured | 3 | 2016 | 6135 | 0.150 |
Why?
|
Follow-Up Studies | 7 | 2024 | 39430 | 0.150 |
Why?
|
Clinical Clerkship | 2 | 2023 | 566 | 0.150 |
Why?
|
Professional Competence | 1 | 2020 | 431 | 0.140 |
Why?
|
False Negative Reactions | 2 | 2018 | 575 | 0.140 |
Why?
|
Cell Transformation, Neoplastic | 3 | 2015 | 2847 | 0.140 |
Why?
|
Signal Transduction | 4 | 2021 | 23638 | 0.140 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2018 | 142 | 0.140 |
Why?
|
Axilla | 1 | 2019 | 629 | 0.130 |
Why?
|
Skin Transplantation | 1 | 2022 | 1097 | 0.130 |
Why?
|
Lymphatic Metastasis | 3 | 2019 | 2930 | 0.130 |
Why?
|
Chemoprevention | 1 | 2018 | 326 | 0.130 |
Why?
|
Cyclooxygenase 2 | 1 | 2018 | 599 | 0.130 |
Why?
|
Technetium Tc 99m Sestamibi | 2 | 2018 | 184 | 0.130 |
Why?
|
ras Proteins | 2 | 2018 | 1058 | 0.120 |
Why?
|
Prognosis | 8 | 2023 | 30028 | 0.120 |
Why?
|
Monitoring, Intraoperative | 1 | 2021 | 952 | 0.120 |
Why?
|
United States | 7 | 2022 | 73121 | 0.120 |
Why?
|
Colonic Neoplasms | 1 | 2007 | 2544 | 0.120 |
Why?
|
Education, Medical, Undergraduate | 2 | 2023 | 1081 | 0.120 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2015 | 138 | 0.120 |
Why?
|
Glucuronosyltransferase | 1 | 2015 | 136 | 0.110 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 64 | 0.110 |
Why?
|
Radionuclide Imaging | 2 | 2018 | 1998 | 0.110 |
Why?
|
Workplace | 1 | 2019 | 872 | 0.110 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 473 | 0.110 |
Why?
|
Technetium | 1 | 2013 | 326 | 0.110 |
Why?
|
Bronchogenic Cyst | 1 | 2012 | 28 | 0.100 |
Why?
|
Survival Rate | 2 | 2019 | 12875 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7451 | 0.100 |
Why?
|
Overweight | 1 | 2023 | 2428 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2016 | 1766 | 0.090 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 757 | 0.090 |
Why?
|
Maximum Tolerated Dose | 1 | 2014 | 890 | 0.090 |
Why?
|
Toll-Like Receptor 4 | 1 | 2015 | 586 | 0.090 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1489 | 0.090 |
Why?
|
Ultrasonography, Doppler | 1 | 2013 | 463 | 0.090 |
Why?
|
Stromal Cells | 1 | 2016 | 1335 | 0.090 |
Why?
|
Education, Medical, Graduate | 4 | 2023 | 2411 | 0.090 |
Why?
|
Shock, Hemorrhagic | 1 | 2012 | 224 | 0.090 |
Why?
|
Phosphorylation | 2 | 2012 | 8332 | 0.090 |
Why?
|
Pheochromocytoma | 1 | 2012 | 328 | 0.090 |
Why?
|
Patient Selection | 2 | 2018 | 4266 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2018 | 5709 | 0.080 |
Why?
|
Obesity | 2 | 2023 | 13065 | 0.080 |
Why?
|
Bariatric Surgery | 1 | 2019 | 1007 | 0.080 |
Why?
|
Sex Factors | 2 | 2019 | 10647 | 0.080 |
Why?
|
Qualitative Research | 1 | 2019 | 3115 | 0.080 |
Why?
|
Cell Adhesion Molecules | 1 | 2015 | 1615 | 0.080 |
Why?
|
Prospective Studies | 8 | 2022 | 54914 | 0.080 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 2586 | 0.080 |
Why?
|
Adiposity | 1 | 2018 | 1888 | 0.080 |
Why?
|
Hypercalcemia | 1 | 2011 | 423 | 0.080 |
Why?
|
Accreditation | 2 | 2022 | 478 | 0.080 |
Why?
|
Intestinal Polyps | 1 | 2008 | 105 | 0.070 |
Why?
|
Quality Improvement | 1 | 2023 | 3858 | 0.070 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3708 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2011 | 11138 | 0.070 |
Why?
|
Body Mass Index | 2 | 2022 | 13030 | 0.070 |
Why?
|
High-Throughput Screening Assays | 1 | 2012 | 940 | 0.070 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2008 | 361 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2023 | 6400 | 0.060 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 2003 | 0.060 |
Why?
|
Enterocytes | 1 | 2007 | 220 | 0.060 |
Why?
|
Colon | 1 | 2013 | 1804 | 0.060 |
Why?
|
Mice, Inbred C57BL | 4 | 2014 | 22365 | 0.060 |
Why?
|
Retroperitoneal Space | 2 | 2018 | 173 | 0.060 |
Why?
|
Metabolome | 1 | 2012 | 1009 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14766 | 0.060 |
Why?
|
Intestines | 1 | 2014 | 1912 | 0.060 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 4780 | 0.060 |
Why?
|
Thiazoles | 1 | 2012 | 1541 | 0.060 |
Why?
|
Cell Movement | 1 | 2016 | 5223 | 0.060 |
Why?
|
Cell Line, Tumor | 2 | 2011 | 17149 | 0.060 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2006 | 321 | 0.060 |
Why?
|
Fellowships and Scholarships | 2 | 2023 | 1134 | 0.060 |
Why?
|
Cohort Studies | 6 | 2022 | 41797 | 0.060 |
Why?
|
Placebos | 1 | 2008 | 1668 | 0.060 |
Why?
|
Neuroendocrine Tumors | 1 | 2010 | 649 | 0.050 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3665 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 2731 | 0.050 |
Why?
|
Clinical Competence | 3 | 2023 | 4841 | 0.050 |
Why?
|
Up-Regulation | 1 | 2012 | 4138 | 0.050 |
Why?
|
Young Adult | 7 | 2020 | 60045 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2022 | 5891 | 0.050 |
Why?
|
Committee Membership | 1 | 2020 | 18 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4615 | 0.050 |
Why?
|
Mitotic Index | 1 | 2021 | 164 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 14728 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2024 | 5308 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2834 | 0.040 |
Why?
|
Sex Ratio | 1 | 2020 | 107 | 0.040 |
Why?
|
Estrogens | 1 | 2007 | 1531 | 0.040 |
Why?
|
Adolescent | 4 | 2019 | 89168 | 0.040 |
Why?
|
Risk | 3 | 2019 | 9642 | 0.040 |
Why?
|
Risk Factors | 3 | 2022 | 74915 | 0.040 |
Why?
|
Pyrimidines | 1 | 2012 | 3050 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15880 | 0.040 |
Why?
|
Feedback | 1 | 2023 | 794 | 0.040 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2021 | 640 | 0.040 |
Why?
|
Gene Fusion | 1 | 2021 | 356 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4931 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2022 | 743 | 0.040 |
Why?
|
Mice | 4 | 2014 | 82045 | 0.030 |
Why?
|
Animals | 5 | 2014 | 169418 | 0.030 |
Why?
|
Necrosis | 1 | 2021 | 1621 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2020 | 65409 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6856 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10784 | 0.030 |
Why?
|
Career Choice | 1 | 2022 | 769 | 0.030 |
Why?
|
Phenotype | 3 | 2020 | 16712 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6537 | 0.030 |
Why?
|
Preoperative Period | 1 | 2018 | 564 | 0.030 |
Why?
|
Culture Media, Conditioned | 1 | 2016 | 522 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2932 | 0.030 |
Why?
|
Mentors | 1 | 2020 | 672 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18388 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2007 | 9558 | 0.030 |
Why?
|
Blood Loss, Surgical | 1 | 2018 | 643 | 0.030 |
Why?
|
Aberrant Crypt Foci | 1 | 2013 | 12 | 0.030 |
Why?
|
Rats | 1 | 2010 | 23839 | 0.030 |
Why?
|
Anthropometry | 1 | 2018 | 1343 | 0.030 |
Why?
|
Perception | 1 | 2020 | 1207 | 0.030 |
Why?
|
Paneth Cells | 1 | 2013 | 100 | 0.030 |
Why?
|
Intra-Abdominal Fat | 1 | 2018 | 623 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2018 | 670 | 0.030 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 1 | 2012 | 40 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2016 | 1343 | 0.030 |
Why?
|
Smad4 Protein | 1 | 2013 | 193 | 0.030 |
Why?
|
Quality of Life | 1 | 2014 | 13497 | 0.030 |
Why?
|
Program Evaluation | 1 | 2020 | 2508 | 0.020 |
Why?
|
Pancreatic Neoplasms | 1 | 2010 | 5442 | 0.020 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2012 | 174 | 0.020 |
Why?
|
GTP Phosphohydrolases | 1 | 2015 | 525 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2019 | 21156 | 0.020 |
Why?
|
Models, Biological | 1 | 2007 | 9505 | 0.020 |
Why?
|
Learning | 1 | 2020 | 1762 | 0.020 |
Why?
|
Gastric Bypass | 1 | 2019 | 829 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2013 | 1755 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 13026 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2785 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2007 | 11674 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2018 | 2048 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2362 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2013 | 770 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9687 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2012 | 469 | 0.020 |
Why?
|
Marriage | 1 | 2009 | 352 | 0.020 |
Why?
|
Algorithms | 1 | 2008 | 14158 | 0.020 |
Why?
|
Risk Assessment | 2 | 2019 | 24311 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 4120 | 0.020 |
Why?
|
Receptors, Prostaglandin | 1 | 2006 | 53 | 0.020 |
Why?
|
Lipoxygenase | 1 | 2006 | 72 | 0.020 |
Why?
|
Laparoscopy | 1 | 2018 | 2056 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13324 | 0.020 |
Why?
|
Pancreatectomy | 1 | 2010 | 824 | 0.020 |
Why?
|
Probability | 1 | 2010 | 2483 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2022 | 22293 | 0.010 |
Why?
|
Time Factors | 2 | 2018 | 40271 | 0.010 |
Why?
|
World Health Organization | 1 | 2010 | 1328 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3438 | 0.010 |
Why?
|
Dinoprostone | 1 | 2006 | 597 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4534 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1997 | 5808 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 2028 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2010 | 6242 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6657 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26351 | 0.010 |
Why?
|
Stem Cells | 1 | 2013 | 3538 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13655 | 0.010 |
Why?
|
HIV-1 | 1 | 1997 | 6966 | 0.010 |
Why?
|
Databases, Factual | 1 | 2015 | 8081 | 0.010 |
Why?
|
Family | 1 | 2009 | 3208 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2015 | 7895 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 4861 | 0.010 |
Why?
|
HIV Long Terminal Repeat | 1 | 1997 | 86 | 0.010 |
Why?
|
Life Style | 1 | 2009 | 3929 | 0.010 |
Why?
|
Gene Products, tat | 1 | 1997 | 111 | 0.010 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 1997 | 120 | 0.010 |
Why?
|
Survival Analysis | 1 | 2010 | 10125 | 0.010 |
Why?
|
Transcription Factor RelA | 1 | 1997 | 254 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1997 | 1056 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15460 | 0.010 |
Why?
|
Proviruses | 1 | 1997 | 320 | 0.010 |
Why?
|
NFATC Transcription Factors | 1 | 1997 | 394 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2009 | 3922 | 0.010 |
Why?
|
Gene Expression Regulation, Viral | 1 | 1997 | 435 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20762 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15965 | 0.010 |
Why?
|
Registries | 1 | 2010 | 8373 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2013 | 6978 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1997 | 2184 | 0.010 |
Why?
|
Hypertension | 1 | 2012 | 8611 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 36840 | 0.010 |
Why?
|
DNA, Viral | 1 | 1997 | 2206 | 0.010 |
Why?
|
Phylogeny | 1 | 1997 | 2846 | 0.010 |
Why?
|
NF-kappa B | 1 | 1997 | 2491 | 0.000 |
Why?
|
Binding Sites | 1 | 1997 | 6030 | 0.000 |
Why?
|
Base Sequence | 1 | 1997 | 12428 | 0.000 |
Why?
|
Promoter Regions, Genetic | 1 | 1997 | 5803 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1997 | 17647 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 1997 | 7599 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 1997 | 9623 | 0.000 |
Why?
|
Transcription Factors | 1 | 1997 | 12174 | 0.000 |
Why?
|